Equillium, Inc.
NASDAQ:EQ
0.72 (USD) • At close January 8, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Equillium, Inc. |
Symbool | EQ |
Munteenheid | USD |
Prijs | 0.716 |
Beurswaarde | 25,382,625 |
Dividendpercentage | 0% |
52-weken bereik | 0.56 - 3.25 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Bruce D. Steel C.F.A. |
Website | https://equilliumbio.com |
An error occurred while fetching data.
Over Equillium, Inc.
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)